Gene News and Research

Latest Gene News and Research

Illumina, Expression Analysis support Cancer GWAS and Data Analysis Grant program

Expression Analysis today announced that it and Illumina, Inc. are jointly funding a Cancer GWAS (Genome-Wide Association Study) and Data Analysis Grant program to support cutting-edge projects that show promise in identifying genetic elements important to cancer research and treatment.

From Illumina, Inc. 3 Nov 2010

Mouse study indicates black raspberries can prevent colorectal cancer

Black raspberries are highly effective in preventing colorectal tumors in two mouse models of the disease, according to a University of Illinois at Chicago study. The findings are published in the November issue of Cancer Prevention Research.

3 Nov 2010

Combining telaprevir regimen with standard therapy improves SVR rate in hepatitis C

For patients with the most common form of hepatitis C being treated for the first time, the addition of an investigational hepatitis C-specific protease inhibitor called telaprevir to the current standard therapy markedly improved their sustained viral response (SVR or viral cure) rate.

3 Nov 2010

Ligand awarded $1,955,834 federal grant under Patient Protection and Affordable Care Act

Ligand Pharmaceuticals Incorporated today announced it has been awarded $1,955,834 in immediately available funds from the U.S. government under HR: 3590 - Patient Protection and Affordable Care Act. The award comprises separate payments of approximately $245,000 for each of eight drug development programs at Ligand.

2 Nov 2010

GSK's Revolade receives Japanese approval for treatment of chronic ITP

Ligand Pharmaceuticals Incorporated today announced its partner GlaxoSmithKline was granted approval from the Japanese Ministry of Health, Labour and Welfare for Revolade® (eltrombopag) for the treatment of the blood disorder, chronic idiopathic thrombocytopenic purpura (ITP).

2 Nov 2010

Senesco resolves NYSE Amex continued listing deficiency

Senesco Technologies, Inc. today announced that the Company has received a letter from the NYSE Amex LLC informing Senesco that it has now resolved matters related to the Company's exchange listing compliance.

2 Nov 2010

IRS awards RXi Pharmaceuticals four Therapeutic Discovery Project grants

RXi Pharmaceuticals Corporation, a recognized leader in RNAi-based therapeutic discovery and development, today announced that it was awarded four Therapeutic Discovery Project (TDP) grants, totaling $977,917, by the United States Internal Revenue Service (IRS) as part of the Patient Protection and Affordable Care Act of 2010.

2 Nov 2010

NanoString’s nCounter CNV CodeSets help detect genetic copy number variations

NanoString Technologies, Inc., a privately held life sciences company marketing a complete solution for detecting and counting large sets of target molecules in biological samples, today announced the launch of a novel solution for detecting genetic copy number variations (CNVs) associated with disease susceptibility, drug response and cancer progression.

From NanoString Technologies 2 Nov 2010

Nu Skin third quarter revenues increase 15% to record $383.6 million

Nu Skin Enterprises, Inc. today announced record third-quarter results, with revenue of $383.6 million, a 15 percent improvement over the prior-year period. Quarterly revenue was positively impacted 4 percent by foreign currency fluctuations. Earnings per share for the quarter were $0.55, a 38 percent improvement over the prior year.

2 Nov 2010

QuantaLife announces launch of Droplet Digital PCR system at 60th ASHG meeting

QuantaLife, Inc. announced today at the 60th Annual American Society of Human Genetics Meeting the launch of their Droplet Digital™ PCR system. The system, which includes a droplet generator and a droplet reader, quantifies DNA molecules using the company's patented high-resolution, Droplet Digital PCR technology – a 3rd generation PCR technology that enables single-molecule resolution of target sequences.

2 Nov 2010

Study explains statistical link between low aerobic exercise capacity and common diseases

Everybody knows that if you're physically fit, you're less likely to get a wide range of diseases. What most people don't know is that some people are "naturally" in better shape than others, and this variation in conditioning makes it difficult to test for disease risk and drug effectiveness in animal models.

2 Nov 2010

New algebraic model of DNA hybridization to measure cellular behavior

Researchers at New York University's Courant Institute of Mathematical Sciences have developed a novel algebraic model of DNA "hybridization," a process central to most biotechnology devices that monitor changes in cell's gene expression or characterize a cell's genome.

2 Nov 2010

New targeted therapy shows positive results in patients with lung cancer

A UC Irvine oncologist's work with a targeted therapy is showing great promise in patients with a deadly form of lung cancer. The results were published Thursday in the New England Journal of Medicine.

2 Nov 2010

NSAIDs drugs prevent colon cancer: Research

Nonsteroidal anti-inflammatory drugs (NSAIDs) prevent colon cancer by triggering diseased stem cells to self-destruct, according to researchers at the University of Pittsburgh Cancer Institute (UPCI) and the University of Pittsburgh School of Medicine.

2 Nov 2010

Innovative lifesaving device for patients with advanced heart failure

Bradley Cantley, 41, headed home from UC San Diego Medical Center connected to a lifesaving heart machine called a left ventricular assisted device (LVAD). For patients with advanced heart failure, the mechanical pump rapidly improves circulation throughout the body and serves as a bridge to transplant. Cantley is the first of many patients, locally and globally, who will benefit from the expanded heart surgery program at UC San Diego Health System.

2 Nov 2010

GSN closes $12M Series C financing

Gene Security Network, Inc. today announced the closing of its $12M Series C financing. The financing round was led by Sequoia Capital and included Claremont Creek Ventures, Founders Fund, and Lightspeed Venture Partners.

2 Nov 2010

Einstein College's new website features latest information on aging research

Albert Einstein College of Medicine of Yeshiva University has launched SuperAgers.com, a new website that features the latest information on more than a decade of aging research at Einstein.

2 Nov 2010

Research on AID enzyme could improve therapy for lymphoma, leukemia

A recent scientific discovery made by researchers at the Institut de recherches cliniques de Montr-al (IRCM) led by Dr. Javier Marcelo Di Noia, Director of the Mechanisms and Genetic Diversity research unit, was published online today by The Journal of Experimental Medicine. The team identified a mechanism regulating activation-induced deaminase (AID), which could be important for the therapy of some types of lymphoma and leukemia.

2 Nov 2010

BioCancell's Phase I/IIa clinical trial of BC-819 shows positive result for pancreatic cancer

BioCancell, a developer of anti-cancer drugs, announced success in attaining the goals of its Phase I/IIa clinical trial of BC-819 as a treatment for pancreatic cancer, which demonstrated an excellent safety profile and preliminary efficacy.

2 Nov 2010

Arrayit sells third advanced microarray manufacturing system to UT Southwestern

Arrayit Corporation announced today that it has sold a third advanced microarray manufacturing system to the University of Texas Southwestern Medical Center at Dallas. The NanoPrint LM60 Microarrayer equipped with Arrayit's Patented Microarray Manufacturing Technology (US Patent 6,101,946) is a computer-driven robotic microarray manufacturing system that enables the screening of 1.5 million lead therapeutic compounds per run, and the NanoPrint LM210 enables more than 5 million.

2 Nov 2010